AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

ACRUX LIMITED Capital/Financing Update 2013

Aug 7, 2013

64293_rns_2013-08-07_c8ed15cd-24db-439e-bc0c-7d5ccbe6d6cd.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

8 AUGUST 2013

ACRUX (ACR) - ASX ANNOUNCEMENT

ACRUX EMPLOYEE SHARE OPTIONS

Acrux (ASX: ACR) today reported that the board has implemented a long term incentive plan with the grant of new share options to employees. The structure of the plan has been designed to meet Listing Rule requirements and the particular constraints of Acrux’s status as a Pooled Development Fund. Prior to the issue of these new share options, Acrux had no other employee share scheme instruments or any other share options outstanding.

Approximately 1.9 million options (approximately1% of issued share capital) will be granted with an exercise price of $4.30 per share, which is 25% higher than the 5-day volume weighted average price on 31 July 2013. The new options will expire on 31 July 2016. Of the new options, 0.6 million will be issued to Executive Chairman Ross Dobinson, subject to shareholder approval at Acrux’s Annual General Meeting.

Contact

Jon Pilcher, CFO: 0438 422 271

About Acrux

Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative liquid technology to administer drugs through the skin.
Acrux has products marketed by licensees in the United States, Europe, Canada and Australia and in registration or development.

==> picture [123 x 66] intentionally omitted <==